1.
Paying a high price for cancer drugs
by The Lancet
Lancet (London, England), 01 August 2015, Vol.386(9992), pp.404
2.
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
by Sánchez-Martínez, Concepción
Bioorganic & medicinal chemistry letters, 01 September 2015, Vol.25(17), pp.3420-35
3.
Identification of amino acid appended acridines as potential leads to anti-cancer drugs.
by Singh, Palwinder
Bioorganic & medicinal chemistry letters, September 15, 2015, Vol.25(18), pp.3854-3858
4.
Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib
by Pan, Xiaoyan
Bioorganic & Medicinal Chemistry Letters, Oct 1, 2015, Vol.25(19), p.4164(5)
5.
Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States
by Bloom, Romi
Journal of the American Academy of Dermatology, 2015, Vol.73(2), p.337(2)
6.
Differences in cancer drug assessment between Spain and the United Kingdom
by Lozano-Blázquez, Ana
European journal of cancer (1990), September 2015, Vol.51(13), pp.1843-1852
7.
Lessons for cancer drug treatment from tackling a non-cancerous overgrowth syndrome.
by Semple, Robert K
Nature, June 2018, Vol.558(7711), pp.523-525
8.
Hypervitaminosis B12 As an Additional Prognostic Indicator in Elderly Adults with a Neoplastic Disease: Report of a Case and Review of the Literature.
by Zulfiqar, Abrar-Ahmad
October 2015
Journal of the American Geriatrics Society, Vol.63(10), pp.2220-2221
2015
9.
10.
Corrigendum to "Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis" [Eur. J. Pharmachol. 748 (2015) 50-60].(Correction...
by Malik, S.
European Journal of Pharmacology, Sept 5, 2015, Vol.762, p.488
11.
An Ex Vivo Model for Anti-Angiogenic Drug Testing on Intact Microvascular Networks.(Report)
by Azimi, Mohammad S.
PLoS ONE, March 5, 2015, Vol.10(3)
12.
Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
by Pivot, Xavier
European journal of cancer (Oxford, England : 1990), September 2015, Vol.51(13), pp.1660-1666
13.
Exposure to anticancer drugs can result in transgenerational genomic instability in mice.
by Glen, Colin D
Proceedings of the National Academy of Sciences of the United States of America, February 21, 2012, Vol.109(8), pp.2984-2988
14.
Stanniocalcin 2 promotes cell proliferation and cisplatin resistance in cervical cancer.
by Wang, Yuxia
Biochemical and biophysical research communications, October 23, 2015, Vol.466(3), pp.362-368
15.
Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current.
by Sittl, Ruth
Proceedings of the National Academy of Sciences of the United States of America, April 24, 2012, Vol.109(17), pp.6704-6709
16.
Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents.
by Xu, Guoyan G
Bioorganic & medicinal chemistry letters, September 1, 2015, Vol.25(17), pp.3721-3725
17.
Human Pol [zeta] purified with accessory subunits is active in translesion DNA synthesis and complements Pol [eta] in cisplatin bypass.(BIOCHEMISTRY)(Author abstract)
by Lee, Young - Sam
Proceedings of the National Academy of Sciences of the United States, Feb 25, 2014, Vol.111(8), p.2954(6)
18.
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
by Sugahara, Kazuki N
Science (New York, N.Y.), May 21, 2010, Vol.328(5981), pp.1031-1035
19.
Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.(Author abstract)(Report)
by Wu, Chyuan - Chuan
Science, July 22, 2011, Vol.333(6041), p.459(4)
20.
Integrated analysis of transcriptome in cancer patient-derived xenografts.
by Li, Hong
PloS one, 2015, Vol.10(5), p.e0124780
